Phoenix Biotech Acquisition Corp.

Status: Deal Closed
U=S+W/2 W=S@11.50
IPO Proceeds, $M $175.00M
IPO Date Oct 6, 2021
CEO Chris Ehrlich
Left Lead Cantor Fitzgerald
IPO Cash in Trust 102.0%
SPAC Tenor 15 + 6 + 6 + 3
IPO Sector Healthcare

Healthcare or healthcare related industries in the United States and Europe

IPO Geography Global
Target Company CERo Therapeutics
Deal Announced Jun 5, 2023
Deal Size, $M $112.00M
Deal Sector Healthcare
Deal Geography US/Canada
SEC Filings www.sec.gov
Approval Vote Feb 8, 2024
Amendment Vote Jan 3, 2024
Closing Date Feb 14, 2024
Formerly PBAX CERO CEROW

Sign up for Free Trial

No credit card required

Sign in for more on Phoenix Biotech Acquisition Corp.:

  • Structure and cap table
  • 7 directors & officers
  • 35 filings and events
  • 1 underwriters
  • 1 deal advisors
  • 3 legal advisors
Structure

Sign in to view structure, cap table, and calendar of events.

Team
Name Age Title
Chris Ehrlich 51 CEO and Director
Daniel Geffken 63 CFO
Douglas Fisher 45 President
Brian G. Atwood 68 Director
Kathleen LaPorte 59 Director
Barbara Kosacz 63 Director
Caroline Loewy 55 Director

Sign in to view team biographies and more sponsor and affiliate data.

Advisors
Underwriters
Cantor Fitzgerald BR 15,500,000 units
15,500,000 units
Up-Front UW fee 2.00 %
Deferred UW fee 5.00 %

Sign in to view more advisor data.

Deal

Sign in to view merger details and deal financials.

Filings

Sign in to view 35 filings.

Shareholders

Sign in to view shareholders 13F filing data.